Literature DB >> 16612252

The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters.

Nitish R Mahapatra1, Manjula Mahata, Sushil K Mahata, Daniel T O'Connor.   

Abstract

BACKGROUND: Secretory granules of chromaffin cells and neurons co-store and release, by exocytosis, the acidic soluble protein chromogranin A (human, CHGA; rodent, Chga) along with catecholamines, neuropeptides and adenosine triphosphate (ATP). CHGA serves as a pro-protein and upon proteolytic cleavage it generates active peptides, including catestatin (human CHGA352-372), first discovered in adrenal medullary chromaffin granules. Studies in our laboratory demonstrated that catestatin acts at the nicotinic acetylcholine receptor to inhibit catecholamine secretion. However, the specificity of catestatin to exert nicotinic-cholinergic antagonism among its co-transmitters is not clearly known, nor is the potential effect of catestatin on multiple vesicle co-transmitters understood. AIM: Here we probed the specificity of catestatin's actions among its co-transmitters: catecholamines, ATP, and neuropeptide Y (NPY).
METHODS: We studied the effects of each transmitter on exocytotic secretion of its co-transmitters from PC12 chromaffin cells, stimulating secretion by triggering physiological pathways at multiple sites.
RESULTS: We observed that, among chromaffin granule co-transmitters, only catestatin and NPY inhibited catecholamine release induced by nicotinic-cholinergic stimulation; catestatin was more than tenfold more potent than NPY in this setting. We also stimulated norepinephrine secretion by other chromaffin cell agonists: catestatin blocked norepinephrine release induced by nicotine, but not by other agents (such as membrane depolarization) acting at later stages in the secretory pathway, nor by agents acting on other receptor classes. By contrast, NPY acted less specifically, blocking norepinephrine release triggered by either nicotine or membrane depolarization. Catestatin inhibited nicotinic-cholinergic co-release of all classes of chromaffin granule co-transmitters: catecholamines, chromogranins, neuropeptides, and ATP. Naturally occurring variants of human catestatin (Gly364Ser and Pro370Leu) exhibited parallel changes in potency to inhibit secretion of catecholamines and ATP.
CONCLUSION: We conclude that, among the chromaffin granule co-transmitters, catestatin acts as the most specific and potent inhibitor of physiological pathway (nicotinic-cholinergic) stimulated secretion. Furthermore, catestatin generally inhibits nicotinically triggered exocytotic release of multiple co-transmitters from chromaffin granules. The results have physiological and pharmacological implications for co-transmission in the sympathochromaffin system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16612252     DOI: 10.1097/01.hjh.0000222760.99852.e0

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  13 in total

Review 1.  Serotonin and Serotonin Transporters in the Adrenal Medulla: A Potential Hub for Modulation of the Sympathetic Stress Response.

Authors:  Rebecca L Brindley; Mary Beth Bauer; Randy D Blakely; Kevin P M Currie
Journal:  ACS Chem Neurosci       Date:  2017-04-13       Impact factor: 4.418

2.  Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses.

Authors:  Sucheta M Vaingankar; Ying Li; Nilima Biswas; Jiaur Gayen; Sonia Choksi; Fangwen Rao; Michael G Ziegler; Sushil K Mahata; Daniel T O'Connor
Journal:  J Hypertens       Date:  2010-04       Impact factor: 4.844

Review 3.  Chromogranin A: a novel susceptibility gene for essential hypertension.

Authors:  Bhavani S Sahu; Parshuram J Sonawane; Nitish R Mahapatra
Journal:  Cell Mol Life Sci       Date:  2009-11-27       Impact factor: 9.261

4.  The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism.

Authors:  Tommaso Angelone; Anna Maria Quintieri; Bhawanjit K Brar; Pauline T Limchaiyawat; Bruno Tota; Sushil K Mahata; Maria Carmela Cerra
Journal:  Endocrinology       Date:  2008-06-05       Impact factor: 4.736

5.  Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure.

Authors:  Daniel T O'Connor; Gu Zhu; Fangwen Rao; Laurent Taupenot; Maple M Fung; Madhusudan Das; Sushil K Mahata; Manjula Mahata; Lei Wang; Kuixing Zhang; Tiffany A Greenwood; Pei-an Betty Shih; Myles G Cockburn; Michael G Ziegler; Mats Stridsberg; Nicholas G Martin; John B Whitfield
Journal:  Circulation       Date:  2008-06-30       Impact factor: 29.690

6.  The trans-Golgi proteins SCLIP and SCG10 interact with chromogranin A to regulate neuroendocrine secretion.

Authors:  Nitish R Mahapatra; Laurent Taupenot; Maite Courel; Sushil K Mahata; Daniel T O'Connor
Journal:  Biochemistry       Date:  2008-06-13       Impact factor: 3.162

7.  Functional genetic variants of the catecholamine-release-inhibitory peptide catestatin in an Indian population: allele-specific effects on metabolic traits.

Authors:  Bhavani S Sahu; Jagan M Obbineni; Giriraj Sahu; Prasanna K R Allu; Lakshmi Subramanian; Parshuram J Sonawane; Pradeep K Singh; Binu K Sasi; Sanjib Senapati; Samir K Maji; Amal K Bera; Balashankar S Gomathi; Ajit S Mullasari; Nitish R Mahapatra
Journal:  J Biol Chem       Date:  2012-10-26       Impact factor: 5.157

8.  Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart.

Authors:  Rosa Mazza; Alfonsina Gattuso; Cinzia Mannarino; Bhawanjit K Brar; Sandra Francesca Barbieri; Bruno Tota; Sushil K Mahata
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-09       Impact factor: 4.733

9.  Cardiac electrical activity in a genomically "humanized" chromogranin a monogenic mouse model with hyperadrenergic hypertension.

Authors:  Nagendu B Dev; Saiful A Mir; Jiaur R Gayen; Jawed A Siddiqui; Maja Mustapic; Sucheta M Vaingankar
Journal:  J Cardiovasc Transl Res       Date:  2014-05-13       Impact factor: 4.132

Review 10.  The purinergic neurotransmitter revisited: a single substance or multiple players?

Authors:  Violeta N Mutafova-Yambolieva; Leonie Durnin
Journal:  Pharmacol Ther       Date:  2014-06-02       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.